The Role of Antithrombin III in Heparin Resistance
Key result
Preoperative intravenous heparin therapy for >24 hours prior to cardiopulmonary bypass was associated with a significant difference in the qualitative/quantitative ratio of antithrombin III (p=0.016).
Why the study?
Does preoperative intravenous heparin therapy affect antithrombin III levels and function in patients undergoing coronary artery bypass grafting?
Population
30 patients who were candidates for coronary artery bypass grafting. Group A received intravenous heparin…
Comparison
Preoperative intravenous heparin therapy for… vs No preoperative exposure to heparin therapy
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
May heighten heparin resistance risk during CPB; leaves open whether ATIII monitoring or repletion alters outcomes.
Study Design
Type
Observational (n=30)
Structured PICO
Does preoperative intravenous heparin therapy affect antithrombin III levels and function in patients undergoing coronary artery bypass grafting?
P
Population
30 candidates for coronary artery bypass grafting, divided into those with and without preoperative intravenous heparin exposure for >24 hours.
E
Exposure
Preoperative intravenous heparin therapy for greater than 24 hours
C
Comparator
No preoperative exposure to heparin therapy
O
Outcome
Antithrombin III (AT III) levels measured quantitatively (Loyal Rocket Immunoelectrophoresis Technique) and qualitatively (AT III Anti-10A Activity Assay), and the ratio of qualitative to quantitative AT IIIsurrogate
Main Result
p-value: p=0.016
Preoperative heparin exposure alters the functional-to-quantitative ratio of antithrombin III, which may contribute to heparin resistance during cardiopulmonary bypass.
Cite This Study
Rivard et al. (1990) conducted an observational in Candidates for coronary artery bypass grafting (n=30). Preoperative intravenous heparin therapy vs. No preoperative heparin exposure was evaluated on Antithrombin III (AT III) qualitative/quantitative ratio (p=0.016). Preoperative intravenous heparin therapy for >24 hours prior to cardiopulmonary bypass was associated with a significant difference in the qualitative/quantitative ratio of antithrombin III (p=0.016).